Shares of Dyne Therapeutics, Inc. (DYN) plunged 5.22% in the intraday session on Monday, following the company's disappointing Q4 2024 earnings report last week.
The biotech firm reported a higher-than-expected loss of $0.88 per share for the quarter ended December 31, 2024, missing analysts' average estimate of a $0.96 loss per share. Revenues for the quarter came in at zero, in line with expectations.
The wider losses appear to have dampened investor sentiment, sparking a selloff in Dyne's shares. The stock has already fallen a staggering 42.2% so far this quarter amid concerns over the company's cash burn and ability to bring new therapies to market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.